New York is currently home to 4476 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including New York, Rochester, Bronx and Buffalo. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Transforming Care for Individuals with Childhood-onset Systemic Lupus Erythematosus
Recruiting
This study aims to investigate the feasibility and effectiveness of a cognitive behavioral coping skills program, Treatment and Education Approach for Childhood-onset Lupus (TEACH), for youth with cSLE when integrated into medical care. This TEACH program aims to teach participants skills in order to cope with fatigue, pain, and depressive symptoms--symptoms that commonly affect adolescents and young adults with lupus.
Gender:
ALL
Ages:
Between 12 years and 22 years
Trial Updated:
02/05/2025
Locations: Montefiore Medical Center, Bronx, New York
Conditions: Systemic Lupus Erythematosus of Childhood (Disorder)
Open-label, Dose Escalation Study of Safety and Preliminary Efficacy of TN-401 in Adults with PKP2 Mutation-associated ARVC
Recruiting
This first-in-human study is designed to evaluate the safety, and preliminary efficacy (PD) of TN-401 gene therapy in adult patients with symptomatic PKP2 mutation-associated ARVC.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
02/05/2025
Locations: NYU Langone Health, New York, New York
Conditions: Arrhythmogenic Right Ventricular Cardiomyopathy
The SUGAR Study; SBRT and Relugolix) for Prostate Cancer
Recruiting
The goal of this clinical trial is to measure the toxicity and effectiveness of the following treatments for cFIR/cgUIR prostate cancer patients. Stereotactic body radiotherapy (SBRT) alone or Stereotactic body radiotherapy (SBRT) combined with Ultrashort GNRH Antagonist called Relugolix (an oral drug). Treatments will be randomly assigned to study patients. The main questions it aims to answer are the following: 1. Whether the proportion of men who undergo SUGAR have a superior rate of attai... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
02/05/2025
Locations: Memorial Sloan Kettering Cancer Center, New York, New York
Conditions: Prostate Cancer
PROACTIVE-HF-2 Trial Heart Failure NYHA Class II and III
Recruiting
This is a prospective, multi-center, open label, randomized control clinical trial evaluating the safety and efficacy of the Cordella™ Pulmonary Artery Sensor System in NYHA Class II-III Heart Failure Patients (PROACTIVE-HF-2 Trial). The study contains of 5 arms: NYHA II Cohort - To demonstrate safety and efficacy of the Cordella PA Sensor System in NYHA Class II HF patients, where patients have daily access to PAP data. * Treatment Arm (Group 1) * Active Control Arm (Group 2) * Crossover Arm... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/05/2025
Locations: Mount Sinai West, New York, New York
Conditions: Heart Failure NYHA Class II, Heart Failure NYHA Class III, Heart Failure
LIVEBETTER: A Trial Comparing Medications in Older Adults With Stable Angina and Multiple Chronic Conditions
Recruiting
To establish the effectiveness and tolerability of standard of care anti-anginal treatment (beta-blocker and calcium channel blocker medications) in older adults with symptomatic Stable Ischemic Heart Disease (SIHD) and multiple chronic conditions (MCC).
Gender:
ALL
Ages:
65 years and above
Trial Updated:
02/05/2025
Locations: Mt. Sinai Health System, New York, New York
Conditions: Angina, Stable Ischemic Heart Disease
Leverage Noninvasive Transcutaneous Vagus Nerve Stimulation to Reduce Suicidal Behaviors in Vulnerable Adolescents
Recruiting
Suicidal thoughts, suicide attempts, and suicide are increasingly common in adolescence. Current face-to-face prevention approaches are of limited effectiveness, rely on extensive resources, and are at odds with adolescents' digital preferences. We will evaluate two unconventional but promising interventions delivered to 13- to 17-year-olds: transcutaneous vagus nerve stimulation to target emotion dysregulation, and a peer-support smartphone app to combat social isolation. If effective, these d... Read More
Gender:
ALL
Ages:
Between 13 years and 17 years
Trial Updated:
02/05/2025
Locations: University of Rochester Medical Center, Rochester, New York
Conditions: Self Harm, Suicidal Ideation
Selinexor for the Treatment of Intermediate and High-Risk Smoldering Multiple Myeloma
Recruiting
Selinexor is a drug that has been approved in the treatment of patients with symptomatic multiple myeloma. The standard of care for patients with Smoldering Multiple Myeloma remains observation, but there are numerous clinical trials investigating interventions to delay progression to multiple myeloma and prevent or delay disease related outcomes. A subset of patients with intermediate or high risk smoldering multiple myeloma have a much higher risk of progressive to multiple myeloma, while the... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/05/2025
Locations: University of Rochester, Rochester, New York
Conditions: Smoldering Multiple Myeloma
Prospective Case Collection Study for New Mammography Technologies
Recruiting
To evaluate the safety and efficacy of the proposed investigational device and assess its clinical utility in breast cancer screening and diagnosis to support continuing technology development of the investigational technology.
Gender:
FEMALE
Ages:
Between 35 years and 100 years
Trial Updated:
02/05/2025
Locations: Elizabeth Wendy Breast Care, Rochester, New York
Conditions: Mammography
A Phase II Clinical Trial Comparing the Efficacy of RO7198457 Versus Watchful Waiting in Patients with CtDNA-positive, Resected Stage II (high Risk) and Stage III Colorectal Cancer
Recruiting
This is a multi-site, open-label, Phase II, randomized, trial to compare the efficacy of RO7198457 versus watchful waiting in patients with circulating tumor DNA (ctDNA) positive, surgically resected Stage II/III rectal cancer, or Stage II (high risk)/Stage III colon cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/05/2025
Locations: New York Oncology Hematology, P.C., Albany, New York
Conditions: Colorectal Cancer Stage II, Colorectal Cancer Stage III
Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG
Recruiting
The primary objective of this study is to evaluate the effectiveness (prevention of thromboembolic events) and safety (major bleeding) of adding oral anticoagulation (OAC) to background antiplatelet therapy in patients who develop new-onset post-operative atrial fibrillation (POAF) after isolated coronary artery bypass graft (CABG) surgery. All patients with a qualifying POAF event, who decline randomization, will be offered the option of enrollment in a parallel registry that captures their ba... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/05/2025
Locations: Montefiore Medical Center, Bronx, New York
Conditions: Atrial Fibrillation, Stroke, Bleeding
Trial of Nivolumab Following Partially Human Leukocyte Antigen (HLA) Mismatched BMT in Children & Adults With Sarcoma
Recruiting
This research is being done to find out if an investigational drug, Nivolumab, can be safely administered after a "half-matched" (haplo) bone marrow transplant (BMT), and if the investigational drug will help to prevent or delay relapse or progression of sarcomas. In this study investigators will also be trying to learn more about how the investigational drug changes blood and/or tumors. Participants are eligible for this trial if they have recently undergone a "half-matched" (haplo) bone marrow... Read More
Gender:
ALL
Ages:
Between 12 months and 40 years
Trial Updated:
02/05/2025
Locations: Albert Einstein College of Medicine, Children's Hospital at Montefiore, Bronx, New York
Conditions: Sarcoma, Solid Tumor, Adult, Solid Tumor, Childhood
Responses to Genetic Risk Modifier Testing Among Women With BRCA1/2 Mutations
Recruiting
The purpose of this study is to describe how women with BRCA1/2 mutations react to genetic risk modifier testing, and to examine how they make decisions about their healthcare.
Gender:
FEMALE
Ages:
25 years and above
Trial Updated:
02/05/2025
Locations: Memorial Sloan Kettering Commack, Commack, New York
Conditions: Genetic Testing, BRCA1/2